| Target Price | $494.70 |
| Price | $183.30 |
| Potential | 169.89% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target MicroStrategy 2026 . The average MicroStrategy target price is $494.70. This is 169.89% higher than the current stock price. The highest price target is $740.25 303.85% , the lowest is $429.25 134.18% . | |
| A rating was issued by 22 analysts: 19 Analysts recommend MicroStrategy to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the MicroStrategy stock has an average upside potential 2026 of 169.89% . Most analysts recommend the MicroStrategy stock at Purchase. |
16 Analysts have issued a sales forecast MicroStrategy 2025 . The average MicroStrategy sales estimate is $476m . This is 0.29% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $499m 5.08% , the lowest is $442m 7.03% .
This results in the following potential growth metrics:
| 2024 | $463m | 6.61% |
|---|---|---|
| 2025 | $476m | 2.78% |
| 2026 | $487m | 2.19% |
| 2027 | $482m | 1.05% |
7 Analysts have issued an MicroStrategy EBITDA forecast 2025. The average MicroStrategy EBITDA estimate is $4.2b . This is 65.19% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $8.6b 28.63% , the lowest is $32.8m 99.73% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | $-45.3m | 395.56% |
|---|---|---|
| 2025 | $4.2b | 9,327.54% |
| 2026 | $11.4b | 171.92% |
| 2027 | $3.5b | 69.59% |
| 2024 | -9.78% | 416.48% |
|---|---|---|
| 2025 | 877.75% | 9,078.19% |
| 2026 | 2,335.65% | 166.10% |
| 2027 | 717.76% | 69.27% |
15 MicroStrategy Analysts have issued a net profit forecast 2025. The average MicroStrategy net profit estimate is $12.5b . This is 61.57% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $25.0b 223.65% , the lowest is $5.2b 32.37% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | $-1.2b | 371.87% |
|---|---|---|
| 2025 | $12.5b | 1,168.90% |
| 2026 | $9.5b | 23.87% |
| 2027 | $10.0b | 5.36% |
| 2024 | -251.73% | 391.11% |
|---|---|---|
| 2025 | 2,618.02% | 1,140.02% |
| 2026 | 1,950.27% | 25.51% |
| 2027 | 2,076.69% | 6.48% |
15 Analysts have issued a MicroStrategy forecast for earnings per share. The average MicroStrategy EPS is $43.43 . This is 77.48% higher than earnings per share in the financial year 2024. The highest EPS forecast is $87.00 255.54% , the lowest is $18.18 25.70% .
This results in the following potential growth metrics and future valuations:
| 2024 | $-6.06 | 333.98% |
|---|---|---|
| 2025 | $43.43 | 816.67% |
| 2026 | $33.06 | 23.88% |
| 2027 | $34.84 | 5.38% |
| Current | 7.55 | 103.94% |
|---|---|---|
| 2025 | 4.25 | 43.68% |
| 2026 | 5.58 | 31.29% |
| 2027 | 5.30 | 5.02% |
Based on analysts' sales estimates for 2025, the MicroStrategy stock is valued at an EV/Sales of 128.43 and an P/S ratio of 111.39 .
This results in the following potential growth metrics and future valuations:
| Current | 128.81 | 37.75% |
|---|---|---|
| 2025 | 128.43 | 0.29% |
| 2026 | 125.68 | 2.14% |
| 2027 | 127.02 | 1.06% |
| Current | 111.71 | 43.58% |
|---|---|---|
| 2025 | 111.39 | 0.29% |
| 2026 | 109.00 | 2.14% |
| 2027 | 110.16 | 1.06% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Bernstein |
Outperform
➜
Outperform
|
Unchanged | Dec 08 2025 |
| Monness, Crespi, Hardt |
Sell
➜
Neutral
|
Upgrade | Nov 10 2025 |
| HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Nov 03 2025 |
| Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Nov 03 2025 |
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Oct 31 2025 |
| BTIG |
Buy
➜
Buy
|
Unchanged | Oct 31 2025 |
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Oct 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Bernstein:
Outperform
➜
Outperform
|
Dec 08 2025 |
|
Upgrade
Monness, Crespi, Hardt:
Sell
➜
Neutral
|
Nov 10 2025 |
|
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Nov 03 2025 |
|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Nov 03 2025 |
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Oct 31 2025 |
|
Unchanged
BTIG:
Buy
➜
Buy
|
Oct 31 2025 |
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Oct 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


